RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech

Page 2 of 2

Moving on to RA Capital’s other micro-cap picks, Regulus Therapeutics Inc (NASDAQ:RGLS) tops the list as the fund held some 3.59 million shares valued at $60.83 million of the $523.36 million biopharmaceutical company engaged in developing microRNAs to treat a range of diseases. The holding, which was slashed by 24% during the first quarter, represents about 7.04% of the company’s outstanding shares and 6.15% of the fund’s portfolio. The stock price of Regulus Therapeutics Inc (NASDAQ:RGLS) has fallen by more than 36% year-to-date. The most recent sizable dip came when CEO Kleanthis G. Xanthopoulos resigned from his position this month. Chief Medical Officer Paul Grint will replace him. Among Regulus Therapeutics Inc (NASDAQ:RGLS)’s stockholders that we track, Bihua Chen‘s Cormorant Asset Management is the second-largest after RA Capital, owning some 896,500 shares valued at $15.19 million.

By the end of the first quarter RA Capital held about 2.43 million shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) valued at $58.36 million. The holding represents more than 13.6% of the company’s outstanding shares. Among the hedge funds that we track, the interest in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) increased by 80% during the first quarter as nine funds had a total of $71.33 million invested in the company at the end of March, as compared with five firms with $46.47 million invested at the end of the previous quarter. Samuel Isaly‘s Orbimed Advisors is the largest shareholder among these, excluding RA Capital, holding some 195,000 shares valued at $4.69 million.

RA Capital initiated a stake in Dynavax Technologies Corporation (NASDAQ:DVAX) during the first quarter by acquiring about 8.87% of the company’s outstanding stock, amounting to 2.6 million shares valued at $58.32 million. The stock price of the $643.50 million company that develops vaccines and therapeutics using toll-like receptor (TLR) biology has appreciated by more than 32% so far this year. Smart money poured into Dynavax Technologies Corporation (NASDAQ:DVAX) during the first three months of the year as 20 funds had an aggregate investment of $257.52 million in the company at the end of March as compared with 11 firms with $108.78 million in shares at the end of the previous quarter. Aside from RA Capital, Paul Orlin and Alex Porter’s Amici Capital is the largest stockholder of Dynavax Technologies Corporation (NASDAQ:DVAX) among these, holding some 2.47 million shares valued at $55.51 million.

Disclosure: None

Page 2 of 2